AMCP 2021 poster: Symptoms and impacts of nonsense mutation Duchenne muscular dystrophy (nmDMD): A qualitative study and the development of a patient-centered conceptual model
This poster, shown at the 2021 virtual AMCP Annual Meeting, presents results of a qualitative interview study investigating the impact on health-related quality of life (HRQoL) of nmDMD, and patients’ and caregivers’ experience of treatment
Review the demographics of 10 caregivers who participated in the interviews, and characteristics of the ambulatory patients with nmDMD
Explore the symptoms and the impact on HRQoL of nmDMD before and after treatment with a mutation-specific DMD therapy, as reported by caregivers
Understand the experience of patients and caregivers with the mutation-specific DMD therapy
Learn about a conceptual model of nmDMD, including moderating factors and management, developed from the responses
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at pharmacovigilance@ptcbio.com
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-DMD-2200031 | March 2022
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.